- Home
- TVGN vs IOBT Comparison
TVGN vs IOBT Comparison
Compare TVGN & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$0.73
Company Overview
Basic Information| Metric | TVGN | IOBT |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.6M | 57.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TVGN | IOBT |
|---|---|---|
| Price | $0.40 | $0.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $5.00 | $3.50 |
| AVG Volume (30 Days) | ★ 1.4M | 769.0K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.32 |
| 52 Week High | $1.92 | $2.79 |
Technical Indicators
Market Signals| Indicator | TVGN | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 43.20 | 50.24 |
| Support Level | $0.37 | $0.61 |
| Resistance Level | $0.40 | $0.72 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 32.47 | 49.98 |
Price Performance
Historical Comparison TVGN
IOBT
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.